Veracyte (VCYT)
(Real Time Quote from BATS)
$29.34 USD
+2.29 (8.47%)
Updated Aug 8, 2024 01:50 PM ET
3-Hold of 5 3
D Value B Growth B Momentum C VGM
Price, Consensus and EPS Surprise
VCYT 29.34 +2.29(8.47%)
Will VCYT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for VCYT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for VCYT
Veracyte (VCYT) Q2 Earnings Beat Estimates, '24 Sales View Up
Veracyte (VCYT) Q2 Earnings and Revenues Beat Estimates
VCYT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Globus Medical (GMED) Global Sales, Innovation Aid Growth
Globus Medical (GMED) Gets FDA Nod for ExcelsiusFlex, ACTIFY 3D
Veracyte (VCYT) Stock Jumps 13.2%: Will It Continue to Soar?
Other News for VCYT
What's Driving Veracyte Inc's Surprising 34% Stock Rally?
Shopify Posts Upbeat Earnings, Joins Axon Enterprise, Aspen Technology, Illumina, Global Payments And Other Big Stocks Moving Higher On Wednesday
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Strong Performance and Upgraded Outlook Justify Buy Rating for Veracyte
Veracyte: Q2 Earnings Snapshot